Temozolomide in Combination With Docetaxel in Patients With Advanced Melanoma: A Phase II Study of the Hellenic Cooperative Oncology Group

Abstract

The combination of temozolomide and docetaxel was effective and well tolerated as first-line treatment for patients with advanced metastatic melanoma and demonstrated encouraging antitumor activity against brain metastases.

Phase Ι trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease

“…Studies in which the two agents, docetaxel and temozolomide were combined are limited. As discussed above, the combination was initially investigated in 2002 in patients with advanced metastatic melanoma [17]. In that study, alopecia was a universal adverse event and neutropenia developed in 13% of the patients similar to our study.…”

“…The combination of docetaxel and temozolomide has been reported in a study by Bafaloukos in 2002 [17]. Sixty five patients with metastatic melanoma were treated with the combination.…”

A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma

“…The previously untreated subjects showed a 7% overall response rate and a median survival of 3.5 months, while the previously treated individuals had a median overall survival of 2.2 months (Agarwala et al 2004). In another report, three of eight patients with brain metastases from melanoma responded to the combination of temozolomide and docetaxel for 5-12 months (Bafaloukos et al 2002). A phase II study examined the eYcacy and safety of the same combination of temozolomide and thalidomide used in our trial, in chemotherapy-naïve patients with brain metastases (Hwu et al 2005).…”

The pathogenesis and treatment of brain metastases: a comprehensive review

“…Among responders, 38% of patients who presented with brain metastases achieved a partial response. Furthermore among 52 patients without brain involvement at presentation, only four (8%) developed brain metastases at a median follow-up of 14 months [131].…”